Business Wire

MA-NEURALA

Share
Vision AI leader Neurala launches European Subsidiary

Today, Neurala , the leader in vision AI software, announced the launch of its European subsidiary, Neurala Europe, based in Italy. By establishing a presence in Europe, Neurala is advancing its efforts in the industrial space, bolstering on-the-ground expertise and support for its European partners, VARs and manufacturing customers as the industry increasingly prioritizes AI and automation as a part of Industry 4.0 initiatives.

Backed by Friulia S.p.A., an investment firm based in Trieste, Italy, and AddValue, an investment firm based in Milan, Italy, the new subsidiary will solidify Neurala’s global footprint and position the company as a catalyst for growth of industrial and manufacturing innovation outside of the United States. Neurala is already working with global strategic partners, including IMA Group , Antares Vision , FLIR Systems and IHI Logistics and Machinery , as well as several European systems integrators.

“As the world begins to reopen, manufacturers need cost-effective solutions that can be easily deployed and can scale to meet fluctuating consumer demands that have become the norm over the last year,” said Max Versace, CEO and co-founder of Neurala. “This new venture will enable Neurala to address that need by working closely with local partners and our team on the ground to bring vision AI onto industrial machines, cameras, and production lines.”

“In many ways, this is a homecoming for me, and for Neurala,” Versace continued. “I was born and raised in the Friuli region and have always had a connection to Italy. Naturally, I am thrilled to officially extend the bridge between Italy and the United States. With the launch of Neurala Europe, my hope is that we are able to marry Neurala’s AI expertise with Europe’s drive for industrial innovation.”

“As one of Neurala’s strategic partners, we have seen firsthand the impact of the company’s vision AI software and innovation in the industrial space,” said Dario Rea, Director of Corporate Research & Innovation, IMA Group. “The addition of a European subsidiary will put Neurala on the ground, in Europe, so that they can continue to develop relationships with local partners and distributors, making them even more competitive at a global scale, and increasing their ability to share this game-changing technology with key players in Europe and beyond.”

As part of the Neurala Europe launch, the company will hire sales, software engineering and research personnel based out of Italy, to help meet the growing demand for AI in manufacturing and visual inspections. Neurala Europe will be managed by Versace and by Daniel Glasser, Neurala’s VP of Client Operations, who will join the Board of Neurala Europe and oversee day-to-day operations.

About Neurala

Neurala is a pioneer in vision AI software. On a mission to make AI more applicable and useful in real-world applications, Neurala helps industrial companies improve their quality inspection process, with technology that dramatically reduces the time, cost and skills required to build and maintain production-quality custom vision AI solutions. Founded in 2006, Neurala’s research team invented Lifelong-DNN™ (L-DNN) technology, which lowers the data requirements for AI model development and enables continuous learning in the cloud or at the edge. Neurala is headquartered in Boston, MA with a European subsidiary in Trieste, Italy.

Follow Neurala on Twitter (@Neurala) and on Facebook , YouTube and LinkedIn .

For more information about Neurala’s AI software, request a demo .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release

MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind

Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release

New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne

NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release

Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an

Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release

First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye